Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of California San Deigo - Moores Cancer Dept. of Moores Cancer Center
mi
from
San Diego, CA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of California San Deigo - Moores Cancer Dept. of Moores Cancer Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Emory University School of Medicine/Winship Cancer Institute Emory 3
mi
from
Atlanta, GA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Emory University School of Medicine/Winship Cancer Institute Emory 3
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Georgia Health Sciences University Georgia Health 2
mi
from
Augusta, GA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Georgia Health Sciences University Georgia Health 2
mi
from
Augusta, GA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University Chicago Hospital Dept. of Univ of Chicago (2)
mi
from
Chicago, IL
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University Chicago Hospital Dept. of Univ of Chicago (2)
mi
from
Chicago, IL
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Indiana University Indiana Univ 2
mi
from
Indianapolis, IN
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Indiana University Indiana Univ 2
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Stormont Vail Healthcare - Cotton-O'Neil Clinic Stormont-Vail
mi
from
Topeka, KA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Stormont Vail Healthcare - Cotton-O'Neil Clinic Stormont-Vail
mi
from
Topeka, KA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Hematology and Oncology Specialists Dept of Hem&Onc Specialist - 2
mi
from
Metairie, LA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Hematology and Oncology Specialists Dept of Hem&Onc Specialist - 2
mi
from
Metairie, LA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Dana Farber Cancer Institute DFCI LG100
mi
from
Boston, MA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Dana Farber Cancer Institute DFCI LG100
mi
from
Boston, MA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University Missouri Ellis Fischel Cancer Center Univ Missouri
mi
from
Columbia, MO
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University Missouri Ellis Fischel Cancer Center Univ Missouri
mi
from
Columbia, MO
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Memorial Sloan Kettering Cancer Center MSKCC
mi
from
New York, NY
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Memorial Sloan Kettering Cancer Center MSKCC
mi
from
New York, NY
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Weill Cornell Medical College Cornell 2
mi
from
New York, NY
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Weill Cornell Medical College Cornell 2
mi
from
New York, NY
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Duke University Medical Center Duke 2
mi
from
Durham, NC
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Duke University Medical Center Duke 2
mi
from
Durham, NC
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Akron City Hospital Summa Health System Akron
mi
from
Akron, OH
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Akron City Hospital Summa Health System Akron
mi
from
Akron, OH
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital
mi
from
Columbus, OH
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Ohio State Comprehensive Cancer Center/James Cancer Hospital Dept.ofJamesCancerHospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Oregon Health & Science University StudyCoordinator:CBHQ880A2203
mi
from
Portland, OR
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Oregon Health & Science University StudyCoordinator:CBHQ880A2203
mi
from
Portland, OR
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
The Baylor College of Medicine/The Methodist Hospital Methodist
mi
from
Houston, TX
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
The Baylor College of Medicine/The Methodist Hospital Methodist
mi
from
Houston, TX
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
MD Anderson Cancer Center/University of Texas Univ TX MD Anderson
mi
from
Houston, TX
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
MD Anderson Cancer Center/University of Texas Univ TX MD Anderson
mi
from
Houston, TX
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3)
mi
from
San Antonio, TX
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Medical Oncology Associates PS
mi
from
Spokane, WA
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Medical Oncology Associates PS
mi
from
Spokane, WA
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
University of Wisconsin Univ Wisc
mi
from
Madison, WI
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
University of Wisconsin Univ Wisc
mi
from
Madison, WI
Click here to add this to my saved trials
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated:  10/10/2012
Dean Health System Hem Onc
mi
from
Madison, WI
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency
A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Status: Enrolling
Updated: 10/10/2012
Dean Health System Hem Onc
mi
from
Madison, WI
Click here to add this to my saved trials
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated:  10/22/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated: 10/22/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated:  10/22/2012
Pfizer Investigational Site
mi
from
Bossier City, LA
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated: 10/22/2012
Pfizer Investigational Site
mi
from
Bossier City, LA
Click here to add this to my saved trials
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated:  10/22/2012
Pfizer Investigational Site
mi
from
West Jordan, UT
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated: 10/22/2012
Pfizer Investigational Site
mi
from
West Jordan, UT
Click here to add this to my saved trials
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/29/2012
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/29/2012
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/29/2012
Emory University
mi
from
Atlanta, GA
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/29/2012
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/29/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/29/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/29/2012
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/29/2012
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/29/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/29/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dasatinib and Cyclosporine in Patients With Chronic Myelogenous Leukemia (CML)
Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib Plus Cyclosporine in Patients With Ph+ Leukemia Refractory to or Intolerant of Imatinib Mesylate (ESCAPE1b Trial)
Status: Enrolling
Updated:  10/29/2012
University of Colorado Denver
mi
from
Aurora, CO
Dasatinib and Cyclosporine in Patients With Chronic Myelogenous Leukemia (CML)
Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib Plus Cyclosporine in Patients With Ph+ Leukemia Refractory to or Intolerant of Imatinib Mesylate (ESCAPE1b Trial)
Status: Enrolling
Updated: 10/29/2012
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated:  10/31/2012
Indiana University Cancer Center
mi
from
Indianapolis, IN
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone (RCP) for Patients With Newly Diagnosed Multiple Myeloma
Status: Enrolling
Updated: 10/31/2012
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Birmingham, AL
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Huntsville, AL
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Tucson, AZ
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Little Rock, AR
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Anaheim, CA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Denver, CO
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
New Britain, CT
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
New Britain, CT
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Naples, FL
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Atlanta, GA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Roswell, GA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Roswell, GA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Jeffersonville, IN
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Shreveport, LA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Missoula, MT
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Lawrence, NJ
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Lawrence, NJ
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Brooklyn, NY
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Concord, NC
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Concord, NC
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Cincinnati, OH
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Columbus, OH
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
mi
from
Bethany, OK
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
mi
from
Bethany, OK
Click here to add this to my saved trials